Finance

Beta
Lists
NEO:NASDAQ
NeoGenomics, Inc.
$10.90
-3.63%
(-0.41) 1D
$10.90
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NEO...
Open
$11.24
High
$11.44
Low
$10.70
Mkt. cap
1.42B
Avg. vol.
1.93M
Volume
1.05M
52-wk high
$13.74
52-wk low
$4.72
EPS
-$0.77
Beta
1.82
Shares outstanding
130.21M
No. of employees
2K
Open
$11.24
High
$11.44
Low
$10.70
Mkt. cap
1.42B
Avg. vol.
1.93M
Volume
1.05M
52-wk high
$13.74
52-wk low
$4.72
EPS
-$0.77
Beta
1.82
Shares outstanding
130.21M
No. of employees
2K
Analyst outlook
Analyst Ratings
Based on 10 analysts giving stock ratings to NEO in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for NEO in the last 3 months.
Highest
Current $10.90
$25.00 (+129.36%)
Average
$14.93 (+36.97%)
Lowest
$11.00 (+0.92%)
News stories
From sources across the web
Profile
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas. Wikipedia
About NeoGenomics, Inc.
CEOChristopher M. Smith
Employees2.5K
Founded2002
HeadquartersFort Myers, Florida, United States
SectorHealth care provider
Websiteneogenomics.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
181.33M
187.80M
190.17M
186.67M
Cost of goods sold
104.47M
107.35M
106.83M
105.81M
Cost of revenue
104.47M
107.35M
106.83M
105.81M
Research and development expenses
9.02M
8.69M
9.18M
9.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
91.36M
86.95M
86.65M
88.77M
Operating expense
100.38M
95.64M
95.82M
98.30M
Total operating expenses
204.86M
202.99M
202.65M
204.11M
Operating income
-23.53M
-15.19M
-12.48M
-17.44M
Other non operating income
482.00K
-335.00K
84.00K
-12.00K
EBT including unusual items
-45.82M
-26.39M
-12.41M
-17.58M
EBT excluding unusual items
-21.72M
-14.57M
-11.47M
-16.78M
Income tax expense
-724.00K
740.00K
-2.52M
-472.00K
Effective tax rate
1.58%
-2.80%
20.35%
2.69%
Other operating expenses
-
-
-
-
Net income
-45.09M
-27.13M
-9.88M
-17.11M
Net profit margin
-24.87%
-14.45%
-5.20%
-9.16%
Earnings per share
0.03
0.03
0.06
0.01
Interest and investment income
2.26M
1.56M
1.52M
1.27M
Interest expense
-933.00K
-603.00K
-599.00K
-598.00K
Net interest expenses
1.33M
960.00K
924.00K
675.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.26M
1.24M
3.91M
-1.03M
Gain or loss from assets sale
-
-
31.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer